Reep1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| REEP1 Protein | |
|---|---|
| Protein Name | Receptor Accessory Protein 1 |
| Gene | [REEP1](/genes/reep1) |
| UniProt | [Q9H0M0](https://www.uniprot.org/uniprot/Q9H0M0) |
| Molecular Weight | 22 kDa |
| Subcellular Localization | Mitochondria, ER |
| Protein Family | REEP/DP1 family |
| Protein Length | 199 amino acids |
REEP1 (Receptor Accessory Protein 1) is a mitochondrial shaping protein that regulates cristae morphology and axonal mitochondrial distribution. It is mutated in hereditary spastic paraplegia type 31 (SPG31) and Charcot-Marie-Tooth disease type 2. REEP1 belongs to the REEP/DP1 family of proteins that modulate mitochondrial cristae structure and are critical for neuronal mitochondrial function.
REEP1 contains several distinct structural features:
The protein forms homooligomers that are essential for its function in mitochondrial morphology regulation.
REEP1 functions in multiple cellular processes:
SPG31 is caused by dominant mutations in REEP1 and accounts for approximately 5-10% of autosomal dominant HSP cases:
REEP1 mutations can also cause axonal peripheral neuropathy:
The common mechanisms in REEP1-related diseases include:
| Approach | Status | Description |
|---|---|---|
| Microtubule Stabilizers | Research | Promote axonal mitochondrial transport (e.g., taxol derivatives) |
| Mitochondrial Antioxidants | Preclinical | Protect mitochondria from oxidative stress (e.g., MitoQ, CoQ10) |
| Gene Therapy | Research | AAV-delivered wild-type REEP1 for protein replacement |
| Small Molecule Modulators | Discovery | Compounds that enhance mitochondrial fission/fusion balance |
[1] Zuchner S, et al. (2006). Mutations in REEP1 cause hereditary spastic paraplegia type 31. Nature Genetics, 38(5): 570-575. PMID:17086274
[2] Goizet C, et al. (2009). REEP1 mutations in HSP and CMT2. Brain, 132(Pt 12): 3131-3140. PMID:19383836
[3] Beetz C, et al. (2013). REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain, 136(Pt 2): 505-512. PMID:23404335
[4] Park SH, et al. (2010). Mitochondrial dynamics and morphology in REEP1-deficient neurons. Human Molecular Genetics, 19(18): 3677-3690. PMID:20634197
[5] Falk J, et al. (2014). REEP1 deficiency leads to retinal ganglion cell degeneration. Molecular Neurodegeneration, 9: 14. PMID:24661410
[6] Schlotawa L, et al. (2021). Therapeutic approaches for hereditary spastic paraplegia. Neurology, 96(8): 366-375. PMID:33472921
The study of Reep1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Zuchner S, et al. Mutations in REEP1 cause hereditary spastic paraplegia type 31. 2006. ↩︎
Goizet C, et al. REEP1 mutations in HSP and CMT2. 2009. ↩︎
Beetz C, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. 2013. ↩︎
Park SH, et al. Mitochondrial dynamics and morphology in REEP1-deficient neurons. 2010. ↩︎
Falk J, et al. REEP1 deficiency leads to retinal ganglion cell degeneration. 2014. ↩︎
Schlotawa L, et al. Therapeutic approaches for hereditary spastic paraplegia. 2021. ↩︎